biostudies-literaturePapasavvas ENIAID NIH HHSNCI NIH HHS2051-2054https://www.ebi.ac.uk/biostudies/studies/S-EPMC8416745biostudies-literatureUnknown35(12)We report on the post-hoc analysis of three clinical studies (NCT01935089, NCT00594880 and NCT00051818) with chronically HIV-infected, immune-reconstituted individuals with similar entry criteria, and demographics interrupting antiretroviral therapy (ART) without or with 5 weeks of weekly pegylated (Peg)-IFN-α2b or Peg-IFN-α2a immunotherapy added onto ART. Results show similar rates of viral suppression between both immunotherapies when continued during a 4-week ART interruption, despite Peg-IFN-α2a maintaining significantly higher trough blood levels.AIDS (London, England)Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption.PMC8416745UM1 AI126620U01 AI110434P30 AI045008P30 CA010815Papasavvas EKostman JRTebas PAzzoni LHowell BJFair MMontaner LJHazuda DJMounzer KRoss BNfalseComparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption.We report on the post-hoc analysis of three clinical studies (NCT01935089, NCT00594880 and NCT00051818) with chronically HIV-infected, immune-reconstituted individuals with similar entry criteria, and demographics interrupting antiretroviral therapy (ART) without or with 5 weeks of weekly pegylated (Peg)-IFN-α2b or Peg-IFN-α2a immunotherapy added onto ART. Results show similar rates of viral suppression between both immunotherapies when continued during a 4-week ART interruption, despite Peg-IFN-α2a maintaining significantly higher trough blood levels.2021-01-01T00:00:00Z2021 Oct2025-04-22T21:49:17.982Z2025-02-19T01:27:36.3ZS-EPMC84167453404935610.1097/qad.000000000000296110.1097/QAD.0000000000002961